Improving the Therapeutic Ratio in Head and Neck Cancer
Free Global Shipping
No minimum orderDescription
Improving the Therapeutic Ratio in Head and Neck Cancer provides a complete review of current approaches to modulating therapeutic sensitivity in head and neck cancer. It presents a broad background of current approaches and by highlighting the potential for clinical translational, introduces a roadmap for how to move promising preclinical findings into the clinic. The book discusses topics such as immunotherapy and molecularly targeted therapies in head and neck cancer, PI3k/mTOR pathway, autophagy inhibition to sensitize HNC to radiation and chemotherapy, TAM and Eph/Ephrin family proteins and metabolic reprogramming to modulate therapeutic sensitivity. Additionally, it details approaches to improve the response to immunotherapy, and Chk1/2 inhibition in radiation and cetuximab resistance. This book is a valuable source to head and neck cancer researchers and advanced students, and to those studying specific approaches in other model systems and disease sites.
Key Features
- Provides key scientific background for clinicians when developing novel clinical trials and important examples for basic scientists of the types of work required to move a concept from the lab to the clinic
- Presents consistent pathway diagrams in each chapter, thus making it easier to understand complicated pathways
- Includes chapter summaries of the critical next steps needed to move studies from their current state into practice changing clinical data
Readership
Cancer researchers; oncologists; graduate students
Table of Contents
1. Overview of head and neck cancer management
2. The role of immunotherapy and molecularly targeted therapies in head and neck cancer
3. Targeting the PI3K/mTOR pathway
4. Autophagy inhibition to sensitize HNC to radiation and chemotherapy
5. Overcoming head and neck cancer stem cells
6. TAM Family proteins and therapy resistance
7. Eph/Ephrin family proteins and theapy resistance
8. Metabolic reprogramming to modulate therapeutic sensitivity
9. FGFR and cMET
10. Targeting GPCRs in HNC
11. Improving the response to immunotherapy
12. Chk1/2 inhibition in radiation and cetuximab resistance
Product details
- No. of pages: 376
- Language: English
- Copyright: © Academic Press 2019
- Published: October 4, 2019
- Imprint: Academic Press
- Hardcover ISBN: 9780128178683
- eBook ISBN: 9780128178690
About the Series Editor
Benjamin Bonavida
Benjamin Bonavida, PhD, has been involved in the field of immunology and cancer biology for several decades and has published extensively in the fields of cancer resistance, chemotherapy, immunotherapy, and various molecular approaches to circumvent the resistance of the cancer cells using sensitizing agents. Accordingly, he was the first to publish a book on tumor sensitization in 2008. More recently, Dr. Bonavida is the Series Editor of 3 series published by Elsevier/Academic Press (“Cancer Sensitizing Agents for Chemotherapy,” “Breaking Cancer Resistance to Therapeutic Antibodies,” and “Breaking Tolerance to Anti-Cancer Immunotherapy”) and several books have been published and many are in development. He has published extensively in the field of NK biology and cytotoxicity in the past, and many of these publications were in collaboration with the co-editor Dr. Anahid Jewett.
Affiliations and Expertise
Professor, Department of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, USA
About the Series Volume Editor
Randall Kimple
Dr. Kimple completed his MD, PhD in Pharmacology, and residency in Radiation Oncology at the University of North Carolina. He is an Associate Professor of Human Oncology at the University of Wisconsin School of Medicine and Public Health where he is a member of the Multidisciplinary Head and Neck Program and the Wisconsin Head and Neck Cancer SPORE Grant. He runs a translational research lab focused on understanding the molecular basis of therapeutic resistance in head and neck cancer.
Affiliations and Expertise
Associate Professor, Department of Human Oncology, UW Carbone Comprehensive Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA